ShiraTronics Launches First-Ever Trial for Chronic Migraine Therapy in Australia.

This development underscores the company's commitment to advancing innovative solutions that provide relief and improved quality of life for the millions o...

November 30, 2023 | Thursday | News
XEOMIN® (incobotulinumtoxinA) receives three new therapeutic indications in Australia

This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Additional...

November 23, 2023 | Thursday | News
Syncona to Acquire Freeline Therapeutics

Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...

November 23, 2023 | Thursday | News
Certara Launches Simcyp™ Software to Enhance Drug Formulation Efficiency

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,  announced the introduction of Simcyp™ Biopharmaceutics software. It is designed...

November 22, 2023 | Wednesday | News
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TMdrug delive...

November 20, 2023 | Monday | News
Vertex and CRISPR Therapeutics Granted Historic Approval for CASGEVY™, the World's First CRISPR/Cas9 Gene-Edited Therapy, by UK MHRA to Combat Sickle Cell Disease and Beta Thalassemia

 - First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell...

November 17, 2023 | Friday | News
T-Therapeutics Secures £48M in Series A for Advancing Next-Gen TCR Therapeutics in Cancer Treatment Transformation.

T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...

November 16, 2023 | Thursday | News
FDA Clears Solid Biosciences' Gene Therapy for Duchenne Muscular Dystrophy

Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age –   &l...

November 15, 2023 | Wednesday | News
Legend Biotech Secures Exclusive Global License for CAR-T Therapies Targeting DLL3.

The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies ...

November 14, 2023 | Tuesday | News
Senti Bio Collaborates with Celest Therapeutics to Advance SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...

November 07, 2023 | Tuesday | News
MoonLake Immunotherapeutics Reveals Breakthrough Phase 2 Results for Nanobody® Sonelokimab in Psoriatic Arthritis

First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of pote...

November 06, 2023 | Monday | News
Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics

Novogene is a leading provider of genomic services and solutions offering extensive next generation sequencing (NGS) capacity and bioinformatics expertise....

November 06, 2023 | Monday | News
Illumina Launches Liquid Biopsy for Comprehensive Solid Tumor Genomic Profiling

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...

November 02, 2023 | Thursday | News
Aldeyra Therapeutics and AbbVie Sign Exclusive Option Agreement for Reproxalap License

Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...

November 02, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in